1. In Vivo
  2. >>Business Strategy

A Look Into The Future Of NASH

 
• By Elizabeth Cairns

The liver disease is one of the hottest areas of drug development. Here are some upcoming catalysts to look out for.

Liver disease
A plethora of drug candidates are in development for NASH • Source: Shutterstock

Sometimes advances in drug development are like London buses: you wait for ages, and then loads turn up at once. This has certainly been the case in the non-alcoholic steatohepatitis (NASH) space, with several mid-stage trials yielding positive – or positive-ish – data in the past few months.

Key Takeaways
  • Madrigal’s resmetirom is likely to become the first drug approved in NASH later this year

But there is much more to come. Players including Novo Nordisk A/S, Boehringer Ingelheim GmbH, Pfizer Inc....

More from Business Strategy

Mapping Biopharma’s AI Strategy: From Custom Datasets to Foundation Models

 
• By David Wild

Biotech companies are pursuing diverse AI strategies beyond expensive custom data generation: foundation model fine-tuning, data-efficient computational methods and targeted proprietary datasets. In Vivo takes a look at some examples.

Late-Stage GLP-1 Drug Trials Outside The Cardiometabolic Space

 
• By David Wild

A look at Novo Nordisk, Eli Lilly and other companies' late-stage clinical studies of GLP-1 drugs in indications ranging from neurodegeneration to oncology, and alcoholic liver disease to autoimmune conditions.

Rising Leaders 2025: Metsera’s Whit Bernard’s Musical Path To Biotech Leadership

 
• By David Wild

Metsera CEO Whit Bernard applies an unconventional leadership philosophy to develop next-generation obesity therapeutics, including monthly GLP-1 injections and oral peptides.

AI In Drug Discovery: The Patent Implications

 
• By David Wild

A Q&A with DeAnn Smith, partner and co-chair of the Patent Trial and Appeal Board Proceedings Practice Group at law firm Foley Hoag.

More from In Vivo

Wide Of The Mark: ‘The Worst EU Medtech Predictions Have Not Come True’

 
• By Ashley Yeo

Jana Grieb, European regulatory and market access legal expert at McDermott Will & Emery, explains why the healthtech and pharma industries are warming to the new EU health commissioner as he faces calls to make the MDR more “user friendly.”

This Belgian Biotech’s Drug Cocktail Could Help Reverse Muscle Aging

 
• By Jo Shorthouse

While big pharma pours billions into creating new anti-aging molecules, a Belgian startup has taken a different path: combining existing safe drugs with AI precision. The early results suggest it might be onto something revolutionary.

Rising Leaders 2025: Doxie Jordan, From UNC Graduate To Global Market Strategist

 
• By Jo Shorthouse

Bristol Myers Squibb executive Doxie Jordan discusses his path to global commercial leadership and the principles guiding pharmaceutical market strategy